Journal article
Monoclonal antibodies in lymphoma: the first decade
Seminars in hematology, Vol.45(2), pp.71-74
04/2008
DOI: 10.1053/j.seminhematol.2008.02.005
PMCID: PMC2577815
PMID: 18381100
Abstract
The past decade has seen improvements in overall survival (OS) for patients with the two most common lymphoma histologies: diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). In FL, at least four independent datasets have confirmed these survival improvements. The monoclonal antibody rituximab has significantly contributed to these improved therapeutic outcomes. This issue will explore the impact of monoclonal antibody therapy on outcome in indolent lymphoma, and detail how this improved outcome has changed clinical practice. Furthermore, the role of monoclonal antibodies in maintenance regimens and the main indications for radiolabeled antibodies will be discussed in detail. Finally, possible future developments in the field will be proposed, including the use of monoclonal antibodies in ablative transplantation and in the treatment of leukemias.
Details
- Title: Subtitle
- Monoclonal antibodies in lymphoma: the first decade
- Creators
- Brian K Link - Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City, IA 52242, USA. Brian-link@uiowa.eduJonathan W Friedberg
- Resource Type
- Journal article
- Publication Details
- Seminars in hematology, Vol.45(2), pp.71-74
- DOI
- 10.1053/j.seminhematol.2008.02.005
- PMID
- 18381100
- PMCID
- PMC2577815
- NLM abbreviation
- Semin Hematol
- ISSN
- 0037-1963
- eISSN
- 1532-8686
- Grant note
- K23 CA102216-05 / NCI NIH HHS K23 CA102216 / NCI NIH HHS CA-102216 / NCI NIH HHS
- Language
- English
- Date published
- 04/2008
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984094372802771
Metrics
23 Record Views